加载中
HKSEHealthcareDrug Manufacturers - Specialty & Generic
最新数据
HK$2.37
+HK$0.065 · +2.82%
Hua Medicine (Shanghai) Ltd., a biopharmaceutical enterprise established in 2011 and headquartered in Beijing, China, specializes in the clinical development of novel therapeutic solutions, with a primary focus on addressing diabetes within the Chinese market. Its lead asset, Dorzagliatin (also known as HMS5552), is an orally administered medication designed for Type 2 Diabetes. The company is also advancing various combination therapies involving Dorzagliatin for T2D, including pairings with Metformin, Sitagliptin, and Empagliflozin, all of which are currently undergoing Phase I clinical trials. Furthermore, Hua Medicine explores the potential of Dorzagliatin in combination with Pioglitazone for Non-alcoholic steatohepatitis (NASH), with GLP-1 for Alzheimer's disease, and for applications in late-stage Type 2 Diabetes and Type 1 Diabetes. Beyond its diabetes pipeline, the company is developing mGLUR5 as a potential treatment for levodopa-induced dyskinesia in Parkinson's disease patients.
最新数据
HK$2.37
+HK$0.065 · +2.82%
盘中时间采用HKT。市场数据可能有所延迟。
Hua Medicine (Shanghai) Ltd., a biopharmaceutical enterprise established in 2011 and headquartered in Beijing, China, specializes in the clinical development of novel therapeutic solutions, with a primary focus on addressing diabetes within the Chinese market. Its lead asset, Dorzagliatin (also known as HMS5552), is an orally administered medication designed for Type 2 Diabetes. The company is also advancing various combination therapies involving Dorzagliatin for T2D, including pairings with Metformin, Sitagliptin, and Empagliflozin, all of which are currently undergoing Phase I clinical trials. Furthermore, Hua Medicine explores the potential of Dorzagliatin in combination with Pioglitazone for Non-alcoholic steatohepatitis (NASH), with GLP-1 for Alzheimer's disease, and for applications in late-stage Type 2 Diabetes and Type 1 Diabetes. Beyond its diabetes pipeline, the company is developing mGLUR5 as a potential treatment for levodopa-induced dyskinesia in Parkinson's disease patients.
日内区间
当前HK$2.37
52周区间
当前HK$2.37
盘中时间采用HKT。市场数据可能有所延迟。
Hua Medicine (Shanghai) Ltd., a biopharmaceutical enterprise established in 2011 and headquartered in Beijing, China, specializes in the clinical development of novel therapeutic solutions, with a primary focus on addressing diabetes within the Chinese market. Its lead asset, Dorzagliatin (also known as HMS5552), is an orally administered medication designed for Type 2 Diabetes. The company is also advancing various combination therapies involving Dorzagliatin for T2D, including pairings with Metformin, Sitagliptin, and Empagliflozin, all of which are currently undergoing Phase I clinical trials. Furthermore, Hua Medicine explores the potential of Dorzagliatin in combination with Pioglitazone for Non-alcoholic steatohepatitis (NASH), with GLP-1 for Alzheimer's disease, and for applications in late-stage Type 2 Diabetes and Type 1 Diabetes. Beyond its diabetes pipeline, the company is developing mGLUR5 as a potential treatment for levodopa-induced dyskinesia in Parkinson's disease patients.
日内区间
当前HK$2.37
52周区间
当前HK$2.37
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（CNY） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 4.8亿 CNY | 2.56亿 CNY | 7661万 CNY | 1759.9万 CNY | — |
| 销货成本 | 2.07亿 CNY | 1.31亿 CNY | 3923.6万 CNY | 991万 CNY | 3847.64万 CNY |
| 毛利 | 2.73亿 CNY | 1.25亿 CNY | 3737.4万 CNY | 768.9万 CNY | −3847.64万 CNY |
| 研究与开发 | 1.42亿 CNY | 2.15亿 CNY | 1.72亿 CNY | 1.3亿 CNY | 1.87亿 CNY |
| 销售、一般及管理费用 | 2.8亿 CNY | 2.7亿 CNY | 2.04亿 CNY | 1.45亿 CNY | 1.35亿 CNY |
| 营业费用 | 4.14亿 CNY | 4.77亿 CNY | 3.75亿 CNY | 2.75亿 CNY | 3.22亿 CNY |
| 利息收入 | 1118.97万 CNY | 1343.8万 CNY | 1651.2万 CNY | 424万 CNY | 503.6万 CNY |
| 利息支出 | 793.52万 CNY | 860.9万 CNY | 790.7万 CNY | 366.7万 CNY | 395万 CNY |
| 折旧和摊销 | 3162.77万 CNY | 1494.4万 CNY | 3623.8万 CNY | 3177.7万 CNY | 1198.4万 CNY |
| 营业利润 | −1.41亿 CNY | −3.53亿 CNY | −2.89亿 CNY | −2.67亿 CNY | −3.21亿 CNY |
| 净利润 | 10.78亿 CNY | −2.5亿 CNY | −2.11亿 CNY | −2.04亿 CNY | −3.31亿 CNY |
公司数据更新于 2026年10月6日。
已公布业绩及可用的市场共识预期。
已公布业绩及可用的市场共识预期。
报告持有此股票敞口的交易所交易基金。
State Street SPDR Portfolio Emerging Markets ETFSPEM57.6万0.00%174.64亿 USD0.07%US$52.915+0.18%
Avantis Emerging Markets Equity ETFAVEM24.57万—291.66亿 USD0.33%US$96.555-0.11%
Avantis Emerging Markets Value ETFAVES16.3万0.01%15.86亿 USD0.36%US$66.665+0.44%
Dimensional World ex U.S. Core Equity 2 ETFDFAX5.24万0.00%124.35亿 USD0.28%US$37.6218+0.46%
Dimensional - Emerging Markets Core Equity 2 ETFDFEM4.2万0.00%97.75亿 USD0.39%US$40.825+0.06%
Dimensional - Emerging Core Equity Market ETFDFAE4.19万0.00%102.6亿 USD0.29%US$40.39-0.02%
State Street SPDR S&P China ETFGXC2.94万0.01%4.5亿 USD0.59%US$86.05-0.46%
Avantis Emerging Markets Small Cap Equity ETFAVEE1792.53—1.4亿 USD0.42%US$70.78+0.67%State Street SPDR Portfolio Emerging Markets ETFSPEMAvantis Emerging Markets Equity ETFAVEMAvantis Emerging Markets Value ETFAVESDimensional World ex U.S. Core Equity 2 ETFDFAXDimensional - Emerging Markets Core Equity 2 ETFDFEMDimensional - Emerging Core Equity Market ETFDFAEState Street SPDR S&P China ETFGXCAvantis Emerging Markets Small Cap Equity ETFAVEEAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
